Research programme: cancer therapeutics - Exelixis

Drug Profile

Research programme: cancer therapeutics - Exelixis

Alternative Names: XL541

Latest Information Update: 09 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Class
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; MTOR protein inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; Sphingosine-1-phosphate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Feb 2011 Research programme: cancer therapeutics - Exelixis is available for licensing as of 22 Feb 2011. http://www.exelixis.com/
  • 22 Feb 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 18 Dec 2008 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top